Two primary cancers appeared after discontinuation of nivolumab in the course of treating Hodgkin lymphoma: a case report.

ABSTRACT:

Background

Nivolumab is a human monoclonal antibody against programmed death-1 (PD-1) that blocks interactions of PD-1 with both PD-L1 and PD-L2 and upregulates tumor antigen-specific T cell to develop appropriate immune response against cancer cells. It has been approved by the US Food and Drug Administration (FDA) in the treatment of various malignancies including Hodgkin lymphoma (HL).

Case description

Our patient is a 75-year-old man diagnosed with nodular sclerosis HL. After relapse of disease on several lines of treatment including autologous stem cell transplant, Nivolumab was started as part of a clinical trial. Partial response (PR) was noted on nivolumab for a few years which was eventually discontinued due to disease progression. A few weeks later, the patient was

SUBMITTER: Potluri LB 

PROVIDER: S-EPMC10364003 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature